To include your compound in the COVID-19 Resource Center, submit it here.

Repairing the heart from within

University College Londonresearchers have used a thymosin b4 peptide fromRegeneRx Biopharmaceuticals Inc.to target a resident population of cardiac progenitor cells and promote tissue repair in mouse models of myocardial infarction.1 The academics now plan to screen for small molecules that target the cell population. RegeneRx could have an out-licensing opportunity for its peptide, as the company is focused on developing formulations of thymosin b4 for indications outside of cardiovascular disease.

Myocardial infarction (MI) patients are typically prescribed drugs like b-blockers and blood thinners to help prevent further injury to an already damaged heart. However, current drugs are unable to reverse existing damage and

Read the full 1025 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE